<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="56876">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01724333</url>
  </required_header>
  <id_info>
    <org_study_id>2012/1390REK</org_study_id>
    <secondary_id>EORTC-SG2012</secondary_id>
    <nct_id>NCT01724333</nct_id>
  </id_info>
  <brief_title>International Validation of the QLQ-OH17 for Oral Health</brief_title>
  <acronym>QLQ-OH17</acronym>
  <official_title>International Validation and Testing of a Supplementary Questionnaire Module for Assessment of Oral and Dental Health in Cancer; the QLQ-OH17</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oslo University Hospital</source>
  <oversight_info>
    <authority>Norway:National Committee for Medical and Health Research Ethics</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assessment of oral and dental problems is seldom routine in clinical oncology, despite the
      potential negative impact of these problems on nutritional status, social function and
      quality of life (QoL). A brief, assessment tool for oral/dental health and related
      QoL-issues to improve symptom management has been requested. The present study will be
      conducted on behalf of and with support from the European Organisation for Research and
      Treatment of Cancer - (EORTC) Quality of Life Group (QLG). The study represents phase IV,
      the final step, in the development of an international, symptom specific questionnaire
      module, focusing on oral and dental problems in relation to cancer and its treatment. Phase
      I-III of this stepwise development process was conducted from 2008 to 2011, as an
      international collaboration and conducted according to the guidelines for module development
      set forth by the EORTC QLG. The resulting module, the QLQ-OH17, is now subject to an
      international field testing and validation study as described in this project description.

      The present version of the QLQ-OH17 consists of 17 items conceptualized into four multi-item
      scales (pain/discomfort, xerostomia, eating and information) and three single items related
      to use of dentures and future worries. The aim of the present study is to conduct phase IV;
      an international field study to confirm the psychometric properties of the QLQ-OH17
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The EORTC guidelines will be strictly followed also in phase IV of the module development.
      Eligible patients will be contacted by the local study coordinator or a study nurse and
      informed about the study. After having provided written informed consent, they will be
      presented with the following two questionnaires for self-report of general symptoms,
      specific dental and oral symptoms, and quality of life issues; the EORTC QLQ-C30  and the
      QLQ-OH17. In addition to these two, a short debriefing interview will be conducted by study
      coordinator / study nurse for assessment of feasibility and patients' opinion about the
      questionnaires.

      The case report form (CRF) on medical and demographic data will be completed by the study
      coordinator / study nurse before or after the patients have completed their part.

      A subset of the patients will be assessed twice, as examination of test - retest reliability
      is important in phase IV of the development process.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Cross-Sectional</study_design>
  <primary_outcome>
    <measure>Oral morbidity</measure>
    <time_frame>Up to two years</time_frame>
    <safety_issue>No</safety_issue>
    <description>The study aims to validate a questionnaire for assessment of oral morbidity, oral health , and quality of life in relation to cancer treatment. Specific outcomes are prevalence of patients with moderate to severe oral morbidity due to cancer treatment (mucositis,stomatitis, taste change, decayed /loose teeth, osteoradionecrosis, ulcers), to investigate if the severity varies with certain background variables , for example, diagnostic group, age, sex, stage of disease, type of treatment, and to investigate the discriminant validity, reliability and responsiveness of the specific items in patient subgroups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>Up to two years</time_frame>
    <safety_issue>No</safety_issue>
    <description>The questionnaire module that is subject to testing of psychometric properties, will be used together with a well-validated quality of life questionnaire, to investigate if oral morbidity affects overall quality of life</description>
  </secondary_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Anticipated">530</enrollment>
  <condition>Quality of Life</condition>
  <condition>EORTC</condition>
  <condition>Oral Health</condition>
  <arm_group>
    <arm_group_label>Group 1a - in active treatment</arm_group_label>
    <description>Questionnaires only</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1b - 2-6 months post-treatment</arm_group_label>
    <description>Questionnaires only</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1C - 6 mos-3yrs post-treatment</arm_group_label>
    <description>Questionnaires only</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1D - Palliative treatment</arm_group_label>
    <description>Questionnaires only</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1D- Referred to dentist/oral team</arm_group_label>
    <description>Questionnaires only</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        An international, cross-cultural sample of cancer patients with different diagnoses in
        different phases of treatment
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Patients with a verified cancer diagnosis other than basal cell carcinoma, incl. H&amp;N
             cancer

          -  Sufficient language ability to understand and complete the questionnaires without
             assistance

          -  No obvious cognitive impairments, as judged by the study coordinator upon inclusion

          -  Age 18 years or above

          -  Provision of written informed consent

          -  No participation in another trial or study possibly interfering with the present
             study

        Exclusion Criteria:

          -  Patients being diagnosed with basal cell carcinoma

          -  Patients who have been included in Phase I-III of the module development

          -  Patients who are in the terminal phase of cancer

          -  Patients who are unable to participate in the interviews do to obvious cognitive
             impairment, psychological disturbance or language problems
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marianne J Hjermstad, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oslo University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marianne J Hjermstad, PhD</last_name>
    <phone>4723026828</phone>
    <email>m.j.hjermstad@medisin.uio.no</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nina Aaass, PhD</last_name>
    <phone>4723026828</phone>
    <email>NAA@ous-hf.no</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Adelaide</name>
      <address>
        <city>Adelaide</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Richard Logan, PhD</last_name>
      <email>richard.logan@adelaide.edu.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Metz</name>
      <address>
        <city>Metz</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sebastien Montel, PhD</last_name>
      <email>montel@univ-metz.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Freiburg</name>
      <address>
        <city>Freiburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Joachim Weis, PhD</last_name>
      <email>weis@tumorbio.uni-freiburg.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Leipzig</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dirk Hofmeister, PhD</last_name>
      <email>Dirk.Hofmeister@medizin.uni-leipzig.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Johannes Gutenberg University Mainz</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Susanne Singer, PhD</last_name>
      <email>mailto:singer@imbei.uni-mainz.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Athens</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ourania Nicolatou-Galitis, PhD</last_name>
      <email>nicolatou.galitis@lycos.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tel-Aviv University</name>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Noam Yarom, PhD</last_name>
      <email>noamyar@post.tau.ac.il</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>VU University Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Irma Verdonck-de Leeuw, PhD</last_name>
      <email>IM.Verdonck@vumc.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Academic Centre for Dentistry Amsterdam</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Judith Raber-Durlacher, PhD</last_name>
      <email>jraber@worldonline.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mia Bergenmar, PhD</last_name>
      <email>Mia.Bergenmar@ki.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Leeds</name>
      <address>
        <city>Leeds</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sheila Fisher, PhD</last_name>
      <email>S.E.Fisher@doctors.org.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Israel</country>
    <country>Netherlands</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <lastchanged_date>November 6, 2012</lastchanged_date>
  <firstreceived_date>November 2, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>EORTC QLQ-C30</keyword>
  <keyword>Oral health</keyword>
  <keyword>Quality of life</keyword>
  <keyword>Questionnaires</keyword>
  <keyword>Patient reported</keyword>
  <keyword>outcomes</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
